# Sources — Gilda Radner

> **SYNTHETIC RECORD, NOT A REAL MEDICAL RECORD**

Accessed November 4, 2026. The canonical source metadata and claim links are in `case.json`.

## Historical evidence

1. Most A. “Gilda Radner.” *The Shalvi/Hyman Encyclopedia of Jewish Women*, Jewish Women’s Archive. Supports her birth on June 28, 1946, into a prosperous Detroit Jewish family (her paternal grandfather emigrated from Lithuania); her father’s death from brain cancer when she was fourteen; her Saturday Night Live years (first cast member, 1975 to 1980, Emmy in 1978); the bouts of bulimia in those years; her marriage to Gene Wilder in 1984; her diagnosis after Haunted Honeymoon; writing *It’s Always Something* between chemotherapy treatments, with the help of The Wellness Community; and her death in Los Angeles on May 20, 1989. https://jwa.org/encyclopedia/article/radner-gilda
2. Zakarin J. “Gilda Radner and Gene Wilder’s Enduring, and Heartbreaking, Love Story.” Biography.com, February 26, 2025. Supports two miscarriages (one during the filming of Haunted Honeymoon in London), an unsuccessful round of IVF, fatigue first attributed to Epstein-Barr virus, bloating so marked she could barely button her trousers, shaking legs, fevers, cramps dismissed by gynecologists, the memoir’s line “Now I had Epstein-Barr virus and mittelschmerz,” the stage IV diagnosis in October 1986 with a tumor “the size of a grapefruit,” nine rounds of chemotherapy and 30 radiation treatments. https://www.biography.com/celebrities/a63938628/gilda-radner-gene-wilder-relationship-timeline
3. Micheli R. “Inside Gene Wilder and Gilda Radner’s Romance,” excerpted from *LIFE: Gene Wilder 1933–2016*. TIME, September 22, 2016. Supports spells of extreme fatigue in early 1986 dismissed by her internist as Epstein-Barr virus; a trip to Paris during which she doubled over in pain; her father’s death from a malignant brain tumor when she was 14; the diagnosis ten months after her symptoms began; stage 4 disease with a grapefruit-size tumor; her death at Cedars-Sinai three days after the CT scan, at 42; her husband’s statement that a blood test or a family history might have caught the cancer in time; that her grandmother, a cousin, and an aunt had all had ovarian cancer; his testimony to a House subcommittee; and the Gilda Radner Ovarian Detection Center at Cedars-Sinai. https://time.com/4502772/gene-wilder-gilda-radner-romance/
4. Fuster J. “Read Gene Wilder’s Heartbreaking Essay About Wife Gilda Radner’s Death.” TheWrap, August 29, 2016. Summarizes his 1991 *People* column: the CA-125 test was never given; ten months from her first examination to the diagnosis; “Gilda didn’t have to die”; the detection program at Cedars-Sinai and Gilda’s Club. https://www.thewrap.com/read-gene-wilders-heartbreaking-essay-about-wife-gilda-radners-death/
5. Gilda’s Club Chicago. “Our History.” Supports the stage IV diagnosis in 1986, the support she found at The Wellness Community through the therapist Joanna Bull, the founding of Gilda’s Club after her death by Gene Wilder, Joanna Bull, and Joel Siegel, the first clubhouse in 1995, and the merger with The Wellness Community in 2009 to form the Cancer Support Community. https://www.gildasclubchicago.org/about-us/our-history/
6. Roswell Park Comprehensive Cancer Center. “About the Familial Ovarian Cancer Registry.” Supports that the registry, founded in 1981, was named the Gilda Radner Registry in 1990 and renamed in 2013. https://www.roswellpark.org/ovarian-cancer-registry/about-registry
7. Wikipedia. “Gilda Radner.” Used for dates it attributes to her memoir: fatigue and upper-leg pain beginning in 1985 while filming in the United Kingdom, ten months of wrong diagnoses, the diagnosis on October 21, 1986, surgery on October 26, the recurrence in December 1988, and her admission for a CT scan in May 1989; and as a pointer to its sources. https://en.wikipedia.org/wiki/Gilda_Radner
8. Jewish Women’s Archive. “Death of comedian Gilda Radner at 42” (This Week in History). Supports her birth in Detroit in 1946 and her death from ovarian cancer on May 20, 1989, at 42. https://jwa.org/thisweek/may/20/1989/gilda-radner
9. Blevins J. “Read This: Gilda Radner’s needless death became Gene Wilder’s crusade.” The A.V. Club, August 31, 2016. Supports the succession of wrong diagnoses (Epstein-Barr virus, depression, constipation treated with laxatives). https://www.avclub.com/read-this-gilda-radner-s-needless-death-became-gene-wi-1798251419
10. HISTMED Master Roster v3. Internal project source. Its entries were provisional and were not treated as independent corroboration.

## Clinical guidance

1. National Comprehensive Cancer Network. Clinical Practice Guidelines in Oncology: Ovarian Cancer/Fallopian Tube Cancer/Primary Peritoneal Cancer, Version 4.2026. Work-up of a pelvic mass (ultrasound, CT, CA-125, CEA), gynecologic oncology assessment before surgery, primary cytoreduction aiming for no residual disease, carboplatin and paclitaxel every three weeks for six cycles, germline and somatic testing, PARP inhibitor maintenance for BRCA-mutated disease after response, and follow-up. https://www.nccn.org/guidelines/guidelines-detail?category=1&id=1453
2. Konstantinopoulos PA, et al. “Germline and Somatic Tumor Testing in Epithelial Ovarian Cancer: ASCO Guideline.” *J Clin Oncol* 2020;38(11):1222–1245 (PMID 31986064). Germline testing for every woman with epithelial ovarian cancer; somatic BRCA1 and BRCA2 testing for those without a germline variant; cascade testing for relatives of carriers. https://pubmed.ncbi.nlm.nih.gov/31986064/
3. Tew WP, et al. “PARP Inhibitors in the Management of Ovarian Cancer: ASCO Guideline.” *J Clin Oncol* 2020;38(30):3468–3493 (PMID 32790492). Olaparib maintenance for two years for newly diagnosed stage III or IV disease with a germline or somatic BRCA variant after a response to platinum chemotherapy. https://pubmed.ncbi.nlm.nih.gov/32790492/
4. Goff BA, et al. “Development of an ovarian cancer symptom index: possibilities for earlier detection.” *Cancer* 2007;109(2):221–227 (PMID 17154394). Pelvic or abdominal pain, urinary urgency or frequency, increased abdominal size or bloating, and difficulty eating or feeling full, present for less than a year and on more than 12 days a month. https://pubmed.ncbi.nlm.nih.gov/17154394/
5. American College of Obstetricians and Gynecologists. Committee Opinion No. 716: The Role of the Obstetrician-Gynecologist in the Early Detection of Epithelial Ovarian Cancer in Women at Average Risk. *Obstet Gynecol* 2017 (PMID 28832487). Persistent symptoms call for prompt evaluation with a transvaginal ultrasound and CA-125, and referral to a gynecologic oncologist when cancer is suspected. https://pubmed.ncbi.nlm.nih.gov/28832487/
6. Salani R, et al. “An update on post-treatment surveillance and diagnosis of recurrence in women with gynecologic malignancies: SGO recommendations.” *Gynecol Oncol* 2017;146(1):3–10 (PMID 28372871). Visits every three months for two years, examination, CA-125 if raised at diagnosis, and imaging only for symptoms or a rising marker. https://pubmed.ncbi.nlm.nih.gov/28372871/
7. Key NS, et al. “Venous Thromboembolism Prophylaxis and Treatment in Patients With Cancer: ASCO Guideline Update.” *J Clin Oncol* 2023 (PMID 37075273). Extended prophylaxis for up to four weeks after major open abdominal or pelvic cancer surgery. https://pubmed.ncbi.nlm.nih.gov/37075273/
8. Hesketh PJ, et al. “Antiemetics: ASCO Guideline Update.” *J Clin Oncol* 2020 (PMID 32658626). An NK1 antagonist, a 5-HT3 antagonist, and dexamethasone for carboplatin at AUC 4 or more. https://pubmed.ncbi.nlm.nih.gov/32658626/
9. Loprinzi CL, et al. “Prevention and Management of Chemotherapy-Induced Peripheral Neuropathy in Survivors of Adult Cancers: ASCO Guideline Update.” *J Clin Oncol* 2020 (PMID 32663120). No agent recommended for prevention; dose reduction for intolerable neuropathy; duloxetine for painful neuropathy. https://pubmed.ncbi.nlm.nih.gov/32663120/
10. Hwang JP, et al. “Hepatitis B Virus Screening and Management for Patients With Cancer Prior to Therapy: ASCO Provisional Clinical Opinion Update.” *J Clin Oncol* 2020 (PMID 32716741). https://pubmed.ncbi.nlm.nih.gov/32716741/
11. National Comprehensive Cancer Network. Prevention and Treatment of Cancer-Related Infections, Version 1.2026 (fever and neutropenia precautions; used at the sick visit). https://www.nccn.org/guidelines/guidelines-detail?category=3&id=1457
12. U.S. Preventive Services Task Force: ovarian cancer screening (2018; screening is not for women with symptoms), breast cancer (2024), statin use (2022), depression (2023), unhealthy alcohol use (2018), intimate partner violence (2018), osteoporosis (2025), and the A and B recommendations. https://www.uspreventiveservicestaskforce.org/uspstf/recommendation-topics/uspstf-a-and-b-recommendations
13. Centers for Disease Control and Prevention. Adult Immunization Schedule by Medical Condition and Other Indication. https://www.cdc.gov/vaccines/hcp/imz-schedules/adult-medical-condition.html
14. Medicare Preventive Services reference (Aether Forge, 2026). https://patrickrutledge.github.io/preventative_services/

The CMID does not have an ovarian cancer monograph, so the specialty guidelines above govern the monitoring.

## Editorial resolutions

- **Recent-death rule.** She died in 1989, so the rule does not apply. Even so, the historical claims are limited to what the fetched sources state. Her memoir, *It’s Always Something*, was not read directly; the quotation from it is taken from Biography.com, and the dates Wikipedia attributes to it (October 21 and 26, 1986) are recorded with Wikipedia as the source.
- **The teaching point.** The sources agree that about ten months passed between her first symptoms and the diagnosis, with fatigue put down to Epstein-Barr virus, abdominal symptoms to depression or constipation, and pelvic cramps to mittelschmerz, and that the CA-125 test was never done (CLM-0004, CLM-0005). The modern episode reverses this: her four weeks of bloating, early fullness, pelvic pain, and urinary frequency meet the Goff symptom index at the first visit, and examination, CA-125, ultrasound, CT, and biopsy lead to a diagnosis in eight days. Her husband’s view that she “didn’t have to die” is recorded as **R**, possible (CLM-0012), because whether an earlier diagnosis would have changed the outcome cannot be known.
- **Family history.** The ovarian cancer in her grandmother, an aunt, and a cousin rests on a LIFE book excerpt that reports her husband’s account (CLM-0003, **D**); the side of the family is not stated, so the family history entries say so. Her father’s brain cancer is from the Jewish Women’s Archive (fourteen when he died) and Wikipedia (a tumor when she was 12; he died two years later). No modern statement, decision, or health fact is attributed to any relative.
- **Genetic results.** The germline panel is negative and the tumor carries a BRCA1 pathogenic variant that is somatic. This was chosen deliberately: a germline variant in her would imply a health fact about her real blood relatives, which the record must not do, while a somatic variant supports the PARP inhibitor teaching. The record therefore documents cascade testing as the step that would follow a germline variant (INT-003, the consultation), and the counselor’s advice that her relatives may still want their own counseling because of the family history. This departs from the assignment’s wording (“cascade testing offered to relatives”) and is a judgment call for the owner. Her real genetic status was never tested; the BRCA genes were identified after her death.
- **Bulimia and pregnancy losses.** Both are documented (CLM-0008, CLM-0007), are marked sensitive, and appear only as past history (PMH-001, PMH-002) and as the synthetic G2 P0 reproductive history. No eating-disorder diagnosis is coded and none is carried into the modern episode.
- **Index age and dates.** The synthetic date of birth is June 28, 1986 (shift 40 years). The index visit on April 6, 2026 maps to April 6, 1986, when she was 39, in the months of fatigue and abdominal symptoms before her real diagnosis. An index age of exactly 40 was not used: at 40 the episode would map to after June 28, 1986, leaving too little time before the November 1, 2026 limit for six cycles of chemotherapy and maintenance, and a later shift would place the presentation after her documented diagnosis. All visits map to April to October 1986, within her lifetime and before her documented diagnosis on October 21, 1986; they are not a claim about where she was. The modern diagnosis in what maps to April 1986 is the intended contrast with the ten months of her real history.
- **Presenting problem.** Persistent bloating and pelvic symptoms with an adnexal mass (R19.00) is the presenting problem at intake, resolved at the consultation on April 14, 2026, when the biopsy result led to the diagnosis of high-grade serous carcinoma of both ovaries (C56.3) and peritoneal metastases (C78.6). The intake documents state only what was known then, including the CA-125 drawn at that visit.
- **Synthetic clinical picture.** All visits, results, imaging, pathology, stage (FIGO IIIC, where the real diagnosis was stage IV), the operation, the regimen and doses (carboplatin AUC 5, 610 mg; paclitaxel 175 mg/m2, 275 mg), the genetic results, her height (160 cm), and her modern spouse are synthetic. The spouse is unnamed and has no role. Qualitative results (pregnancy test, hepatitis B, hepatitis C and HIV tests, rapid influenza and COVID-19 tests, genetic results) are in the note text only.
- **Sick visit.** A cold on day 8 of the second cycle (J06.9), chosen because it is common, interacts with treatment (the expected low white count, with no fever, and a plain fever plan), and insinuates no undocumented real diagnosis.
- **Preventive visit.** A periodic adult preventive visit at 40 (CPT 99396 and 99497 in plain text), four weeks into olaparib: the first monthly blood count on olaparib, a lipid screen (no statin), a screening mammogram ordered at 40, cervical screening not needed after hysterectomy for a non-cervical cancer, a baseline bone density scan after surgical menopause, influenza, COVID-19, PCV20, and the first recombinant zoster dose (immunocompromising therapy), no live vaccines, and advance care planning with an unnamed agent.
- **Focused visits.** The four chronic-care follow-ups (diagnosis and consultation, the first chemotherapy day three weeks after surgery, cycle 4, and the end of chemotherapy) are documented as focused visits on the NCCN ovarian cancer guideline, the ASCO germline and somatic testing, PARP inhibitor, antiemetic, neuropathy, VTE and hepatitis B guidelines, the SGO surveillance recommendations, and USPSTF depression screening. Synthetic findings introduced: surgical menopause (E89.41) at three weeks after surgery and grade 1 paclitaxel neuropathy (G62.0) at cycle 4. One protocol deviation is recorded instead of an invented result: CA-125 was not drawn before cycles 2 and 3, which were given in the infusion center with blood counts only; the value at cycle 4 was already normal, so no harm resulted, and the corrective action is CA-125 at the end of treatment and at each surveillance visit (no earlier values are recorded). The bone density scan planned after treatment is recorded as due at the end of chemotherapy and ordered at the preventive visit.
- **Consultation.** The gynecologic oncology referral and the consultation by Sunita Varghese, MD (a fictional consultant), on the diagnosis day, are **S**. The consultant answers the five referral questions in line with what the record shows afterwards: clinical stage IIIC; primary cytoreductive surgery a week later with complete gross resection; germline panel and tumor testing (germline negative, somatic BRCA1); hepatitis and HIV screening before chemotherapy (negative); six cycles of carboplatin and paclitaxel, all given on schedule; olaparib maintenance if a BRCA variant was found (started after a complete response); enoxaparin for four weeks; and distress screening with a support group. Her recommendation of CA-125 before each cycle was not fully followed, as the cycle 4 note records.
- **Real people.** Gene Wilder, Joanna Bull, and Joel Siegel appear only in the claims. Her modern spouse and health care agent are unnamed. No other figure with a record in the dataset is named.
- **Not used.** Her memoir itself, Wilder’s memoir and his 1991 *People* column (known only through TheWrap and TIME), *Gilda’s Disease*, her medical records, and details of her final illness beyond the facts in CLM-0010 were not fetched and are not used. The name of the Cedars-Sinai program is given as the TIME excerpt gives it; sources differ on its later name. Accounts that symptoms were dismissed as stress or medication side effects, found only on low-quality sites, are not claimed.
